269 related articles for article (PubMed ID: 23690952)
1. miR-655 Is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2.
Harazono Y; Muramatsu T; Endo H; Uzawa N; Kawano T; Harada K; Inazawa J; Kozaki K
PLoS One; 2013; 8(5):e62757. PubMed ID: 23690952
[TBL] [Abstract][Full Text] [Related]
2. Loss of MicroRNA-101 Promotes Epithelial to Mesenchymal Transition in Hepatocytes.
Zhao S; Zhang Y; Zheng X; Tu X; Li H; Chen J; Zang Y; Zhang J
J Cell Physiol; 2015 Nov; 230(11):2706-17. PubMed ID: 25808945
[TBL] [Abstract][Full Text] [Related]
3. Tumor-suppressive roles of ΔNp63β-miR-205 axis in epithelial-mesenchymal transition of oral squamous cell carcinoma via targeting ZEB1 and ZEB2.
Hashiguchi Y; Kawano S; Goto Y; Yasuda K; Kaneko N; Sakamoto T; Matsubara R; Jinno T; Maruse Y; Tanaka H; Morioka M; Hattori T; Tanaka S; Kiyoshima T; Nakamura S
J Cell Physiol; 2018 Oct; 233(10):6565-6577. PubMed ID: 29150940
[TBL] [Abstract][Full Text] [Related]
4. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1.
Yokobori T; Suzuki S; Tanaka N; Inose T; Sohda M; Sano A; Sakai M; Nakajima M; Miyazaki T; Kato H; Kuwano H
Cancer Sci; 2013 Jan; 104(1):48-54. PubMed ID: 23013135
[TBL] [Abstract][Full Text] [Related]
5. miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2.
Qiu G; Lin Y; Zhang H; Wu D
Biochem Biophys Res Commun; 2015 Jul; 463(3):315-21. PubMed ID: 26022123
[TBL] [Abstract][Full Text] [Related]
6. miR-544a induces epithelial-mesenchymal transition through the activation of WNT signaling pathway in gastric cancer.
Yanaka Y; Muramatsu T; Uetake H; Kozaki K; Inazawa J
Carcinogenesis; 2015 Nov; 36(11):1363-71. PubMed ID: 26264654
[TBL] [Abstract][Full Text] [Related]
7. Loss of miR-200b promotes invasion via activating the Kindlin-2/integrin β1/AKT pathway in esophageal squamous cell carcinoma: An E-cadherin-independent mechanism.
Zhang HF; Alshareef A; Wu C; Li S; Jiao JW; Cao HH; Lai R; Xu LY; Li EM
Oncotarget; 2015 Oct; 6(30):28949-60. PubMed ID: 26334393
[TBL] [Abstract][Full Text] [Related]
8. PRRX1 deficiency induces mesenchymal-epithelial transition through PITX2/miR-200-dependent SLUG/CTNNB1 regulation in hepatocellular carcinoma.
Chen W; Wu J; Shi W; Zhang G; Chen X; Ji A; Wang Z; Wu J; Jiang C
Cancer Sci; 2021 Jun; 112(6):2158-2172. PubMed ID: 33587761
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressor miR-128-3p inhibits metastasis and epithelial-mesenchymal transition by targeting ZEB1 in esophageal squamous-cell cancer.
Zhao L; Li R; Xu S; Li Y; Zhao P; Dong W; Liu Z; Zhao Q; Tan B
Acta Biochim Biophys Sin (Shanghai); 2018 Feb; 50(2):171-180. PubMed ID: 29329360
[TBL] [Abstract][Full Text] [Related]
10. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2.
Korpal M; Lee ES; Hu G; Kang Y
J Biol Chem; 2008 May; 283(22):14910-4. PubMed ID: 18411277
[TBL] [Abstract][Full Text] [Related]
11. miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting
van Kampen JGM; van Hooij O; Jansen CF; Smit FP; van Noort PI; Schultz I; Schaapveld RQJ; Schalken JA; Verhaegh GW
Cancer Res; 2017 Apr; 77(8):2008-2017. PubMed ID: 28209612
[TBL] [Abstract][Full Text] [Related]
12. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1.
Deng S; Li X; Niu Y; Zhu S; Jin Y; Deng S; Chen J; Liu Y; He C; Yin T; Yang Z; Tao J; Xiong J; Wu H; Wang C; Zhao G
Oncotarget; 2015 Nov; 6(37):39661-75. PubMed ID: 26498682
[TBL] [Abstract][Full Text] [Related]
13. miR-146a promotes proliferation, invasion, and epithelial-to-mesenchymal transition in oral squamous carcinoma cells.
Wang F; Ye LJ; Wang FJ; Liu HF; Wang XL
Environ Toxicol; 2020 Oct; 35(10):1050-1057. PubMed ID: 32469461
[TBL] [Abstract][Full Text] [Related]
14. MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma.
Guo F; Cogdell D; Hu L; Yang D; Sood AK; Xue F; Zhang W
Oncol Rep; 2014 May; 31(5):2021-8. PubMed ID: 24677166
[TBL] [Abstract][Full Text] [Related]
15. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
Gregory PA; Bert AG; Paterson EL; Barry SC; Tsykin A; Farshid G; Vadas MA; Khew-Goodall Y; Goodall GJ
Nat Cell Biol; 2008 May; 10(5):593-601. PubMed ID: 18376396
[TBL] [Abstract][Full Text] [Related]
16. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor-resistant cells cause EMT-induction via suppression of E-cadherin by miR-200 and ZEB1.
Asakura T; Yamaguchi N; Ohkawa K; Yoshida K
Int J Oncol; 2015 May; 46(5):2251-60. PubMed ID: 25738863
[TBL] [Abstract][Full Text] [Related]
18. Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma.
Tamagawa S; Beder LB; Hotomi M; Gunduz M; Yata K; Grenman R; Yamanaka N
Int J Mol Med; 2014 Apr; 33(4):879-86. PubMed ID: 24424572
[TBL] [Abstract][Full Text] [Related]
19. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors.
Ohashi S; Natsuizaka M; Naganuma S; Kagawa S; Kimura S; Itoh H; Kalman RA; Nakagawa M; Darling DS; Basu D; Gimotty PA; Klein-Szanto AJ; Diehl JA; Herlyn M; Nakagawa H
Cancer Res; 2011 Nov; 71(21):6836-47. PubMed ID: 21890822
[TBL] [Abstract][Full Text] [Related]
20. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
[No Abstract] [Full Text] [Related]
[Next] [New Search]